Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery

This study has been terminated.
(low accrual)
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC Identifier:
First received: October 18, 2006
Last updated: July 17, 2012
Last verified: July 2012

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether combination chemotherapy is more effective before or after surgery in treating non-small cell lung cancer.

PURPOSE: This randomized phase II trial is studying the side effects of pemetrexed disodium and cisplatin and comparing how well they work when given before or after surgery in treating patients with stage IB or stage II non-small cell lung cancer that can be removed by surgery.

Condition Intervention Phase
Lung Cancer
Drug: cisplatin
Drug: pemetrexed disodium
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Phase II Study of Pemetrexed and Cisplatin as Either Induction or Adjuvant Chemotherapy in Stage IB-II Non-Small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:

Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Primary Outcome Measures:
  • Successful treatment delivery [ Designated as safety issue: No ]
  • Toxicity (no grade 4) during chemotherapy [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Overall toxicity (all grades) [ Designated as safety issue: Yes ]
  • Progression-free survival and overall survival [ Designated as safety issue: No ]
  • Overall clinical response rate (neoadjuvant chemotherapy arm) [ Designated as safety issue: No ]
  • Pathologic complete response (neoadjuvant chemotherapy arm) [ Designated as safety issue: No ]
  • Resectability rate (neoadjuvant chemotherapy arm) [ Designated as safety issue: No ]
  • Surgical morbidity and mortality [ Designated as safety issue: No ]
  • Fraction of patients that actually receives chemotherapy (adjuvant chemotherapy arm) [ Designated as safety issue: No ]

Enrollment: 13
Study Start Date: August 2006
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Detailed Description:



  • Compare the tolerability (in terms of drug delivery and toxicity) of neoadjuvant vs adjuvant chemotherapy comprising cisplatin and pemetrexed disodium in patients with resectable stage IB or II non-small cell lung cancer.


  • Determine the overall toxicity of this regimen in these patients.
  • Determine the progression-free and overall survival of patients treated with this regimen.
  • Determine the overall clinical response rate, pathologic complete response, and resectability rate in patients treated with neoadjuvant chemotherapy.
  • Determine the surgical morbidity and mortality of patients treated with these regimens.
  • Determine the fraction of patients in the adjuvant arm that receives chemotherapy.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to institution, histological subtype (squamous vs nonsquamous) and clinical stage (IB vs II). Patients are randomized to 1 of 2 treatment arms.

  • Arm I (neoadjuvant chemotherapy): Patients receive cisplatin IV over 3-6 hours and pemetrexed disodium IV on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Four to six weeks after completion of chemotherapy, patients undergo surgery.
  • Arm II (adjuvant chemotherapy): Patients undergo surgery. Beginning 4-8 weeks after surgery, patients receive cisplatin and pemetrexed disodium as in arm I.

After completion of study treatment, patients are followed periodically for 5 years and then annually thereafter.

PROJECTED ACCRUAL: A total of 132 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Pathologically confirmed non-small cell lung cancer (NSCLC)

    • Stage IB or II disease
  • Resectable disease
  • At least 1 measurable lesion
  • No mediastinal involvement by mediastinoscopy and/or positron emission tomography with fludeoxyglucose F 18 scan
  • No evidence of metastatic disease


  • WHO performance status 0-2
  • Absolute neutrophil count > 1,500/mm³
  • Platelet count > 100,000/mm³
  • Hemoglobin > 10 g/dL
  • Creatinine clearance ≥ 60 mL/min
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 3.0 times ULN
  • AST and ALT ≤ 3.0 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other malignant disease, except for the following:

    • Basocellular carcinoma of the skin
    • Adequately treated carcinoma in situ of the cervix
    • Low-grade prostate cancer
    • Other cancer for which the patient has been disease-free for ≥ 5 years
  • No congestive heart failure or angina pectoris unless medically controlled
  • No myocardial infarction within the past 6 months
  • No uncontrolled hypertension or arrhythmia
  • No active uncontrolled infection requiring antibiotics
  • No illness or medical condition that would preclude study participation
  • No pre-existing motor or sensory neurotoxicity ≥ grade 2


  • No prior surgery for NSCLC
  • No prior or other concurrent chemotherapy for NSCLC
  • No prior or concurrent radiotherapy for NSCLC
  • No concurrent immunotherapy
  • No concurrent targeted agents
  • No concurrent hormonal cancer therapy
  • No concurrent routine colony-stimulating factor (e.g., prophylactic filgrastim [G-CSF])
  • No aspirin or nonsteroidal anti-inflammatory drugs within 5 days before or after chemotherapy
  • No other concurrent experimental treatments
  • No other concurrent anticancer treatments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00389688

Universitair Ziekenhuis Antwerpen
Edegem, Belgium, B-2650
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Study Chair: Paul Germonpre, MD Universitair Ziekenhuis Antwerpen
  More Information

No publications provided

Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT00389688     History of Changes
Other Study ID Numbers: EORTC-08051, EORTC-08051, 2005-003822-25
Study First Received: October 18, 2006
Last Updated: July 17, 2012
Health Authority: United States: Federal Government

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
stage I non-small cell lung cancer
stage II non-small cell lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Folic Acid Antagonists processed this record on October 16, 2014